3 April 2023 - EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review ...
20 March 2023 - A top FDA official said Monday that the agency needs to start using accelerated approval, a ...
7 March 2023 - Genethon today announced that the EMA has granted PRIME (Priority Medicines) status to the gene therapy, ...
7 March 2023 - FDA extends PDUFA target action date to 30 June 2023. ...
21 February 2023 - PDUFA date set for 8 October 2023. ...
20 February 2023 - Hemgenix underscores CSL's promise to deliver life-changing innovations that have the potential to help patients lead ...
14 February 2023 - More than 1,000 cell and gene therapy clinical trials registered. ...
13 February 2023 - A top official from the US FDA said he wants to see something similar to the agency’s ...
7 February 2023 - Rocket Pharmaceuticals today announced that the US FDA has granted regenerative medicine advanced therapy designation to ...
30 January 2023 - Nanoscope Therapeutics today announced that the US FDA has granted fast track designation to MCO-010, an ...
17 January 2023 - FBX-101 is granted priority medicines (PRIME) designation by the EMA after review of Phase 1/2 RESKUE clinical ...
16 December 2022 - Today, the US FDA approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating adenoviral vector based gene therapy indicated for ...
16 December 2022 - Regulatory milestone moves CSL one step closer to bringing the promise of gene therapy for haemophilia ...
5 December 2022 - EMA acceptance follows FDA's acceptance of tofersen new drug application earlier this year. ...
1 December 2022 - Orchard Therapeutics today announced its marketing authorisation application for Libmeldy (atidarsagene autotemcel) has been accepted for ...